Skip to main content
. 2020 Jun 12;123(5):730–741. doi: 10.1038/s41416-020-0906-7

Fig. 6. Ibuprofen combined HDAC/HDM (KDM6A/B) inhibitors that restrained cancer progression in vivo.

Fig. 6

a Schema of the inhibitor therapy model established by subcutaneous implantation of A549-luci cells into the NOD/SCID mice. b The representative luciferase images showing the A549-luci tumours at the primary sites of each group. c Tumour growth curve of A549-luci cells under combination therapy of ibuprofen and HDAC/HDM inhibitors. d The body weight of BALB/c mice inoculated with A549-luci cells under combination therapy of ibuprofen and HDAC/HDM inhibitors. e The survival curve of BALB/c mice inoculated with A549-luci cells under combination therapy of ibuprofen and HDAC/HDM inhibitors. f Proposed model of ibuprofen in mediating cancer cell stemness and cancer progression. All data shown are representative of three experiment repeats.